Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABOD2011 in Advanced Solid Tumors
NCT05392699Phase 1Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2022
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABO2011 in solid tumor (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-limiting toxicities at 28 days, Adverse Events at 36 months and 1 more. Started May 2022; status: completed.
02
Drugs
ABO2011
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05392699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392699.